228 related articles for article (PubMed ID: 27572406)
1. Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.
Mustafa MH; Chalhoub H; Denis O; Deplano A; Vergison A; Rodriguez-Villalobos H; Tunney MM; Elborn JS; Kahl BC; Traore H; Vanderbist F; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2016 Nov; 60(11):6735-6741. PubMed ID: 27572406
[TBL] [Abstract][Full Text] [Related]
2. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
[TBL] [Abstract][Full Text] [Related]
3. Characterization of carbapenem nonsusceptible Pseudomonas aeruginosa in Denmark: a nationwide, prospective study.
Hansen F; Johansen HK; Østergaard C; Arpi M; Hansen DS; Littauer P; Holm A; Heltberg O; Schumacher H; Fuursted K; Lykke MA; Tønning B; Hammerum AM; Justesen US
Microb Drug Resist; 2014 Feb; 20(1):22-9. PubMed ID: 23964748
[TBL] [Abstract][Full Text] [Related]
4. Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom.
Woodford N; Zhang J; Kaufmann ME; Yarde S; Tomas Mdel M; Faris C; Vardhan MS; Dawson S; Cotterill SL; Livermore DM
J Antimicrob Chemother; 2008 Dec; 62(6):1265-8. PubMed ID: 18819973
[TBL] [Abstract][Full Text] [Related]
5. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Juan C; Zamorano L; Pérez JL; Ge Y; Oliver A; ;
Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
[TBL] [Abstract][Full Text] [Related]
6. Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
Picão RC; Poirel L; Gales AC; Nordmann P
Antimicrob Agents Chemother; 2009 Sep; 53(9):3908-13. PubMed ID: 19596871
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.
Cabot G; López-Causapé C; Ocampo-Sosa AA; Sommer LM; Domínguez MÁ; Zamorano L; Juan C; Tubau F; Rodríguez C; Moyà B; Peña C; Martínez-Martínez L; Plesiat P; Oliver A
Antimicrob Agents Chemother; 2016 Dec; 60(12):7415-7423. PubMed ID: 27736752
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
Int J Antimicrob Agents; 2023 May; 61(5):106772. PubMed ID: 36878411
[TBL] [Abstract][Full Text] [Related]
9. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
10. [Molecular epidemiology of beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates].
Er H; Altındiş M; Aşık G; Demir C
Mikrobiyol Bul; 2015 Apr; 49(2):156-65. PubMed ID: 26167816
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
12. Clonal Dissemination of Pseudomonas aeruginosa Sequence Type 235 Isolates Carrying blaIMP-6 and Emergence of blaGES-24 and blaIMP-10 on Novel Genomic Islands PAGI-15 and -16 in South Korea.
Hong JS; Yoon EJ; Lee H; Jeong SH; Lee K
Antimicrob Agents Chemother; 2016 Dec; 60(12):7216-7223. PubMed ID: 27671068
[TBL] [Abstract][Full Text] [Related]
13. Detection and characterization of class A extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals.
Glupczynski Y; Bogaerts P; Deplano A; Berhin C; Huang TD; Van Eldere J; Rodriguez-Villalobos H
J Antimicrob Chemother; 2010 May; 65(5):866-71. PubMed ID: 20200037
[TBL] [Abstract][Full Text] [Related]
14. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.
Lozano C; Azcona-Gutiérrez JM; Van Bambeke F; Sáenz Y
PLoS One; 2018; 13(9):e0204167. PubMed ID: 30212579
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Extended-Spectrum Beta Lactamase- and Carbapenemase-Producing Pseudomonas aeruginosa Strains from a Malaysian Tertiary Hospital.
Phoon HYP; Hussin H; Hussain BM; Thong KL
Microb Drug Resist; 2018 Oct; 24(8):1108-1116. PubMed ID: 29437541
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals.
Vatcheva-Dobrevska R; Mulet X; Ivanov I; Zamorano L; Dobreva E; Velinov T; Kantardjiev T; Oliver A
Microb Drug Resist; 2013 Oct; 19(5):355-61. PubMed ID: 23600605
[TBL] [Abstract][Full Text] [Related]
18. First Detection of GES-5 Carbapenemase-Producing Acinetobacter baumannii Isolate.
Al-Agamy MH; Jeannot K; El-Mahdy TS; Shibl AM; Kattan W; Plésiat P; Courvalin P
Microb Drug Resist; 2017 Jul; 23(5):556-562. PubMed ID: 27854148
[TBL] [Abstract][Full Text] [Related]
19. Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. aeruginosa high-risk clones with VIM-5- and IMP-7-type carbapenemases in a tertiary hospital.
Çekin ZK; Dabos L; Malkoçoğlu G; Fortineau N; Bayraktar B; Iorga BI; Naas T; Aktaş E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115174. PubMed ID: 32980808
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Imipenem-Resistant Pseudomonas aeruginosa Clinical Isolates from Egypt Coharboring VIM and IMP Carbapenemases.
El-Domany RA; Emara M; El-Magd MA; Moustafa WH; Abdeltwab NM
Microb Drug Resist; 2017 Sep; 23(6):682-686. PubMed ID: 28085553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
